For the millions of Americans living with fatty liver disease, particularly those with the more severe form known as MASH, semaglutide represents a promising new treatment option.

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

Previous smaller but positive studies by Professor Newsome, published in The Lancet and NEJM, had shown that using semaglutide as a treatment for MASH would have benefit for these patients.

How Can Wegovy Help? How does Wegovy (or any form of 2.4 mg dose of semaglutide) help with MASH?That's exactly what this trial set to find out. Researchers conducted a randomized, double-blind ...

Patients with metabolic dysfunction–associated steatohepatitis (MASH) saw reductions in liver fibrosis and steatohepatitis after 72 weeks of treatment with semaglutide (Ozempic, Wegovy; Novo ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH).In this ongoing phase 3, multicenter ...

Using semaglutide injections, ... MASH is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD), which was previously known as non-alcoholic fatty liver disease, ...

Adult patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or advanced liver fibrosis showed improved liver histology with a once-weekly dose of semaglutide (Wegovy ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease. Skip to content ... MASLD/MASH can be caused by several factors, ...